
Research view
Title: | Prevalence and risk factors of erectile dysfunction among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin |
Author: | Nagy Fawzy, Hesham A. Atia, Sherif M. Galal, Jihan A. Shawky |
Abstract: |
Aim
The aim of the study was to determine the prevalence and risk factors of erectile dysfunction
(ED) among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin.
Patients and methods
The sample consisted of 85 male patients treated with pegylated interferon-α2a and
ribavirin for 12 months, recruited from Tropical and Internal Medicine outpatients of Zagazig
University Hospitals. ED was prospectively studied by International Index of Erectile Function
questionnaire, depression was assessed by Hospital Anxiety and Depression Scale, and
routine laboratory investigations in addition to serum total and free testosterone were evaluated
before, during, and 6 months after treatment.
Results
Prevalence of ED among chronic hepatitis C male patients was 40% (34 patients). There was
signifi cant deterioration of International Index of Erectile Function scores an d Hospital Anxiety
and Depression Scale with respect to basal values and a signifi cant decrease in total and free
testosterone with gradual improvement toward the end of treatment period. Emotional state
and physical profi les were the most signifi cant risk factors for sexual dysfunction.
Conclusion
ED is common amon g hepatitis C virus patients treated with pegylated interferon-α and ribavirin
and it is multifactorial.
Keywor ds :
hepatitis C, male patients, pegylated interferon-α, ribavirin, sexual dysfunction
|
Journal: | Egyptian Journal of Psychiatry 2015, 36:40–44 |
Text: | |
Download Link |